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The brain and body respond to potential and actual stressful events by activating hormonal and neural medi-
ators and modifying behaviors to adapt. Such responses help maintain physiological stability (‘‘allostasis’’).
When behavioral or physiological stressors are frequent and/or severe, allostatic responses can become
dysregulated and maladaptive (‘‘allostatic load’’). Allostatic load may alter brain networks both functionally
and structurally. As a result, the brain’s responses to continued/subsequent stressors are abnormal, and
behavior and systemic physiology are altered in ways that can, in a vicious cycle, lead to further allostatic
load. Migraine patients are continually exposed to such stressors, resulting in changes to central and periph-
eral physiology and function. Here we review how changes in brain states that occur as a result of repeated
migraines may be explained by a maladaptive feedforward allostatic cascade model and how understanding
migraine within the context of allostatic load model suggests alternative treatments for this often-debilitating
disease.Migraine, Stress, and Allostasis
Migraine is a disabling headache disorder characterized by inter-
mittent attacks with a number of physiological and emotional
stressors associated with or provoking each attack (i.e., pain,
tiredness, nausea, vomiting, photophobia, or phonophobia,
etc.). The disease affects millions of individuals, by some esti-
mates 45 million Americans (Stewart et al., 1994) or 11%–17%
of adults in Western societies (Lipton et al., 2001). Estimated
healthcare costs related to migraine are around $1 billion in the
United States, and estimated costs to United States society is
$13 billion annually (Hu et al., 1999). Migraine may be divided
into two subgroups: those with aura (focal neurophysiological
symptoms that usually precede or sometimes accompany the
headache, e.g., visual aura) and those without aura (http://
ihs-classification.org). Frequency of headaches has been used
to further differentiate episodic migraine (attacks with or without
aura that occur 1–14 days/month for >3 months) or chronic
migraine (attacks that occur >15 days/month for >3 months)
(Figure 1). The division is somewhat arbitrary in terms of the
disorder but reflects increasing deterioration of a patient’s
condition as the chronic form is associated with increased
comorbid features (Scher et al., 2005). In terms of features
associated with the disease, migraine differs from other primary
headaches that include tension-type headaches (the most
common headache disorder), trigeminal autonomic cephalalgias
(e.g., cluster headaches), and secondary headaches related to
a specific condition (e.g., infection, trauma, drug withdrawal,
analgesic overuse, cranial neuralgias, etc.). Further details on
these can be found at http://ihs-classification.org.
The underlying pathophysiology of the migraine is largely
unknown. As a neurological condition, migraine may be con-
sidered as a continuum not only in terms of the periheadachechanges with each attack but also in the progression to high
frequency and chronic daily headache that takes place in
some patients (Manack et al., 2011) (Figure 2). Current evidence
suggests that the brains of patients with migraine are signifi-
cantly different from healthy controls. Some of these differences
are in the form of abnormally increased cortical excitability to
pain (Moulton et al., 2011), light (Denuelle et al., 2011), or smell
(Demarquay et al., 2008). Other differences relate to abnormality
in responses that should be adaptive but become impaired or
maladaptive, such as altered brainstem processing (Moulton
et al., 2008). In addition, associated changes in gray matter
volume (May, 2009), impaired adaptive cerebral hemodynamic
mechanisms (Silvestrini et al., 2004), and habituation deficiency
(Coppola et al., 2005) have been described. Thus, migraine
should be considered a brain disease and not simply a recurrent
acute pain syndrome.
The brain is a central organ of stress (McEwen and Gianaros,
2011). The brain determines what is stressful or potentially
stressful and initiates responses that could be in the form of
behavioral and/or physiologic responses that could be either
adaptive or maladaptive. Brain responses are mediated via the
autonomic nervous system and neuroendocrine mechanisms.
In this context, allostasis is the ability to protect the body through
increased activity of mediators that normally promote adaptation
(McEwen and Stellar, 1993), and allostatic load and overload
refers to the wear and tear on the systems (including the brain)
that normally support adaptation and normal function as a result
of repeated stress and/or allostasis. This conceptualization has
a number of advantages: first, it emphasizes that the mediators
that help the organism survive can also contribute to pathophys-
iology; second, it incorporates the effects of health-related
behaviors such as diet, exercise, and physical activity; third, itNeuron 73, January 26, 2012 ª2012 Elsevier Inc. 219
Figure 1. Migraine Frequency and Allostatic Load
Migrainesmay be episodic or chronic based on the number of headache days permonth.With increasing frequency, there are increasing effects on brain function
and structure. These changes reflect increasing allostatic load.
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smoking and substance abuse) that are often triggered by
stressors and that also activate and often dysregulate the
same mediators. In the context of modeling brain disorders in
the framework of allostatic load, allostatic load is illustrated by
reduced hippocampal volume and altered white matter integrity
in type 2 diabetes (Gold et al., 2007; Yau et al., 2010), in chronic
inflammation (Marsland et al., 2008a, 2008b), and in major
depression (Sheline et al., 1996), by metabolic syndrome
associated with bipolar disorder (Brietzke et al., 2011b) and by220 Neuron 73, January 26, 2012 ª2012 Elsevier Inc.alcohol-induced dopamine deficiency in the mesolimbic system
that is due to a growth-derived neurotrophic factor (GDNF)
deficiency (Brietzke et al., 2011a). Such alterations in systemic
and brain physiology modulate and change brain function and
structure in the developing and adult brain (Ganzel and Morris,
2011; McEwen, 2002, 2007).
Allostatic load is not an entity unto itself but is defined by
specific system responses. Different disease states (including
subtypes of disease) may have different types or intensities of
‘‘stressors’’ that may contribute to the allostatic load. MultipleFigure 2. Migraine Attacks
The effects of migraine attacks relate to frequency
(top panels), pre- and postictal processes, and
ongoing effects of these ictal and peri-ictal
challenges. Differences in the temporal nature and
magnitude of these challenges drive the allostatic
state, probably as a result of overactivity and
dysregulation of glutamate, GABA, and glucocor-
ticoids, among other mediators. Allostatic chal-
lenges may be considered continuous (type 1),
intermittent of short duration (type 2), and inter-
mittent of long duration (type 3). Type 1 may
include ongoing processes, such as the increased
excitability of cortical and subcortical structures;
type 2 would include the actual ictal event: pain
and associated symptoms. An example of type
3 are the premonitory symptoms, which include
a wide and heterogeneous collection of cognitive,
psychological, and physical changes preceding
and forewarning of an attack by a few hours to
2–3 days. At least one premonitory symptom is
reported in over 85% of patients, and over 70% of
patients reported two or more; the most frequently
reported premonitory symptoms include fatigue
(46.5%), phonophobia (36.4%), yawning (35.8%),
decreased concentration (51%), and stiff neck
(Giffin et al., 2003; Schoonman et al., 2006).
Figure 3. Migraine and Criteria for Allostatic Load
Four major processes contribute to allostatic load in migraine: (1) migraine attacks produce repeated stress; (2) the brain fails to habituate to stimuli; (3) dys-
regulation of normal adaptive responses, in which components of the stress response may fail to shut down normally, occurs; and (4) compensatory increased
responses may occur (e.g., photophobia) during ictal and interictal states. All of these processes act on the brain system to increase the allostatic load. The
process is further aggravated by the bidirectional effects of migraine on systemic processes that contribute to alterations in brain processing.
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cortex in drug dependence [George and Koob, 2010]), or there
may be changes in systemic metabolic networks affecting brain
function and mood (McIntyre et al., 2007). Adaptive processes
normally come into play with the onset of a stressor and may
bemeasurable in some physiological responses (e.g., circulating
catecholamines or glucocorticoids). Under normal circum-
stances, the adaptive process habituates to repetitive stimuli.
While the consequences of an individual stressor may be subtle,
changes at the cellular and systems levels that then accumulate
over time can result in a new steady state that may be adaptive
(allostasis) or maladaptive (allostatic load). As summarized
elsewhere (McEwen and Wingfield, 2003), allostatic load and
its more extreme form, allostatic overload, are even seen in
animals in the wild, where they can play adaptive roles (e.g.,
bears putting on fat for the winter as an example of allostatic
load that occurs when energy demand exceeds supply; allo-
static overload is illustrated by migrating salmon dying after
mating because of excess glucocorticoids).
In the case of a condition like migraine, it is the internal state of
dysregulation as depicted in Figure 3 that creates an allostatic
load with consequences for brain, behavior, physiological regu-
lation, and systemic physiology that is maladaptive and pro-
gressively damaging in a feedforward cascade. This cascade
is characterized by (1) alterations in normal homeostatic mech-
anisms (e.g., altered sleep, abnormal autonomic function), (2)
failure to habituate to repeated stressors of the same kind, (3)
failure to shut down the stress response in a normal manner,
and (4) altered or inefficient response to stress that eventuallyleads to compensatory increased responses to other mediators
at the cellular level (e.g., central sensitization, chronification, and
stroke). These concepts will be discussed in the following
sections of this paper. There are similar examples of such dys-
regulation on brain systems in other conditions, such as the
effects of chronic opioids on brain systems at a cellular/receptor
level (Gintzler and Chakrabarti, 2004), as well as spinal
morphology (Sklair-Tavron et al., 1996) and alterations in
behavior, including addiction (Nestler, 2004) and other aspects
of brain function and brain morphology (Upadhyay et al.,
2010). In migraine, the disease state alters brain function and
structure, and repeated attacks can lead to disease progres-
sion, transformation, or chronification (see Migraine Progression
and Transformation, below). This review is an analysis of
migraine, a vexing disorder that affects many individuals, but it
is also a paradigm for understanding allostatic interactions in
other clinical disorders.
Allostatic load resulting in cumulative physiological dysfunc-
tion has been considered in other diseases (McEwen, 2003,
2004), as well as in chronic pain (see Allostatic Load and Other
Pain Conditions, below). Specific examples of the latter condi-
tions (McEwen and Kalia, 2010) include arthritis (Von Korff
et al., 2009) and fibromyalgia (Martinez-Lavin and Vargas,
2009). In the latter, for example, early onset of depression or
anxiety disorders correlated with increased risk of adult-onset
arthritis, suggesting that psychological stressors may initially
affect the brain and may contribute to a nonbrain disease state.
As discussed in the following sections, migraine offers a unique
model of the effects of allostatic load on a primary brain disorderNeuron 73, January 26, 2012 ª2012 Elsevier Inc. 221
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shows progression and transformation from acute to chronic
forms; (3) it alters the function and structure of multiple brain
systems; (4) it can be worsened by medication overuse; and (5)
the feedforward cascade is a summation of a number of factors
(viz., frequency, pain, associated symptoms) that results in a
viscous cycle that may increase the allostatic load. Altered allo-
stasis in migraine is also a consequence of multiple processes,
including biological (e.g., gender [Weitzel et al., 2001], genetic
[Maher and Griffiths, 2011]), psychological (e.g., depression,
anxiety [Casucci et al., 2010]), or social (e.g., household income
[Lipton and Bigal, 2005]) in nature.
Allostatic Load Criteria and Migraine
As explained previously, allostatic load is the biological conse-
quence (alterations in structure, function, or both) of chronic
exposure to repeated or chronic stress conditions. We propose
that headaches, foremost migraine, are a disease of allostatic
load, with many of the characteristics of migraine fulfilling criteria
that lead to allostatic load. These criteria will be elaborated
below.
Repeated Frequency of Stress Response
to Multiple Stressors
In episodic migraine there is a stress response to multiple head-
aches, whichmay themselves be triggered by stressors. Specific
stressors associated with migraine include psychological/
emotional (e.g., anxiety) and physiological (e.g., noise, food,
odors, bright light). Perceived stress is what migraineurs list as
the most common trigger of their attack (Sauro and Becker,
2009).
Failure to Habituate to Repeated Stressors
of the Same Kind
Repeated migraine attacks can act as stressors and lead to
a vicious cycle. Failure to habituate to physiological stimuli in
the interictal period is well known. For example, abnormal habit-
uation to stimuli is observed in migraine (Afra et al., 2000; Cop-
pola et al., 2009; Schoenen et al., 2010; Wang and Schoenen,
1998), although in some types of migraine (viz., familial hemi-
plegic migraine), there is increased habituation (Hansen et al.,
2011). Although the underlying mechanism(s) is unclear, it
has been proposed that lack of habituation in migraine may
reflect increased neuronal excitability, decreased inhibition, or
decreased preactivation levels.
Dysregulation of Normal Adaptive Responses
In migraine, both central (brain) and peripheral processes are
altered. The interictal brain is hyperexcitable in migraine, and
there is a lack of habituation in neuronal information processing
(Burstein et al., 2010; Chen et al., 2011; Coppola et al., 2009).
This concept applies to both migraine chronification and
migraine regression. Chronification of migraine, in which head-
aches become more frequent (>14 headache days/month), is
a result of abnormal repeated stressors and use or overuse of
certain medications (e.g., triptans, opioids) and is likely to be
exacerbated by genetic factors. Chronification of migraine is
suggestive of progressivemaladaptation of the brain. Elimination
of stressors may diminish chronification, as reported in women
whose menstrual periods were effectively controlled by
hormonal preventives, leading to a reversal from chronic222 Neuron 73, January 26, 2012 ª2012 Elsevier Inc.migraine to episodic migraine in nearly 60% of individuals (Cal-
houn and Ford, 2008). Similarly, exercise can diminish the
frequency of migraine attacks (Malpass, 2011). It should be
noted that although there are no known mechanisms for
migraine transformation, a number of defined stressors may
contribute to this, including childhood abuse (Tietjen and
Peterlin, 2011), socioeconomic status/social stress (Chyu and
Upchurch, 2011), and posttraumatic stress disorder (PTSD)
(Peterlin et al., 2011).
Given the above points, we argue that migraine is perhaps an
‘‘ideal’’ brain allostatic load disease model. The allostatic load
associated with migraine arises from the disruption of behavior
and dysregulation of adaptive physiological systems that
appears with severe headache pain and subsequent
responses. Because migraine affects behavioral and systemic
health for a significant portion of the patients’ lives (>15 years
[Kelman, 2006]), it is a compelling model of increased allostatic
load (McEwen and Gianaros, 2011). If studied more systemat-
ically with this approach in mind, such thinking may provide
new approaches to modulating or treating the condition,
including the definition of a migraine allostatic load index (Jus-
ter et al., 2011).
What differentiates tension-type headaches (TTH) (http://ihs-
classification.org), the most prevalent primary headache condi-
tion (Jensen, 1999), from migraine includes: usually bilateral,
not aggravated by routine, physical activity; only one of the
symptoms related to sensitivity to sound, light, or smell; and
few autonomic symptoms (nausea and vomiting). The same allo-
static model may be applied to TTH, because the disease may
produce significant changes in brain function and structure:
altered gray matter volume in pain processing areas (Schmidt-
Wilcke et al., 2005), chronification (Ashina et al., 2010), impaired
pain modulation (Buchgreitz et al., 2008), and central sen-
sitization (Filatova et al., 2008). Allostatic load and other pain
conditions are discussed in the Allostatic Load and Other Pain
Conditions section, below.
There are two major processes relating to allostasis in
migraine: (1) adaptive (allostatic) responses to each migraine
attack and its perimigraine phenomena (see Figure 2) and (2)
maladaptive responses (allostatic load) over time with disease
modification (i.e., progression or chronification). Major adaptive
and maladaptive perturbations of brain and body systems
occur in migraine in a number of ways. These include pain (Kel-
man, 2006), cardiovascular changes (Melek et al., 2007), and
immunological changes (Pradalier and Launay, 1996) that
over time lead to an altered brain state characterized by
increased cortical excitability, changes in brain morphology,
and changes in behavior. In this context, the brain ‘‘is the key
organ of stress processes. It determines what individuals will
experience as stressful, it orchestrates how individuals will
cope with stressful experiences, and it changes both function-
ally and structurally as a result of stressful experiences’’ (McE-
wen and Gianaros, 2011). Better understanding the cascading
pathophysiological changes in brain structure and function
with the progression of migraine attacks may contribute to an
improved understanding of full nature and consequences
of this condition that frequently affects an individual’s brain
and body.
Figure 4. Migraine and Allostatic Effectors
The figure summarizes multiple actions on the brain in migraine. The relative contribution of each ‘‘effector’’ to allostatic load is unknown but may be additive or
cumulative over time. ‘‘Effectors’’ may have a continuous (e.g., genetic contributions), episodic (e.g., pain), or progressive (e.g., white matter lesions and stroke)
effect.
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Reverberating Consequences
As noted above, migraine fits an allostatic load model in a
number of ways. In this section we evaluate pathological
changes in brain systems that may take place in the condition
that contribute to the allostatic changes in migraine, including
that migraine attack is a stressor, that the perimigraine events
may contribute to alterations on brain systems, and that alter-
ations in brain function and structure may occur as a conse-
quence of repeated migraine attacks (see Figure 4). The lack of
a normally responsive allostasis (i.e., efficient turning on and
shutting off of responses) in migraine results from a constellation
of processes that include disease-related pathophysiology (e.g.,
central sensitization, chronification, stroke), treatment effects or
endogenous hormonal changes (e.g., medications that may
contribute to chronification), and alterations in normal homeo-
static mechanisms (e.g., altered sleep, abnormal autonomic
function).
Stress and Migraine
Migraine is itself a stressful event. Migraine is a continuum of
processes that precede and succeed the headache phase and
as such should be considered as a multievent process around
the headache itself (Figure 4). Stressful experiences related toactivities of daily living (i.e., emotional and physical) may trigger
migraine (Sauro and Becker, 2009) in a high percentage (nearly
70%) of individuals (Theeler et al., 2010). Between 50% and
70% of subjects show significant, substantial, meaningful
temporal correlations between their daily levels of stress and
their daily migraine activity (Holm et al., 1997). Individuals
respond to migraine stressors in various ways. Some responses
may be considered as protective, involving sensory avoidance
(e.g., photophobia [Purdy, 2011]) or sleep (Herbert and Holzer,
2002; Sahota and Dexter, 1990). Others reflect modulation of
underlying physiological responses, such as activating protec-
tive responses associated with neurogenic inflammation that
may be associated with migraine (Herbert and Holzer, 2002) or
decreasing physical activity (Kelman, 2006). However, in all
cases these responses may be overwhelmed as a viscous cycle
of repeated stress continues to either alter, or perhaps damage,
the brain, both structurally and functionally.
Intermittent and Persistent Modulators in Migraine
Migraine should not only be considered a process in which
acute stressors ‘‘attack’’ the brain. Some of these insults may
produce effects after migraine attack ends. Indeed, accumu-
lating evidence suggests increased alterations in brain with
migraine (see Brain Regions in Migraine: Targets of AllostaticNeuron 73, January 26, 2012 ª2012 Elsevier Inc. 223
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migraine (Kruit et al., 2010). One example is the effects associ-
ated with aura. Patients with aura have more deleterious effects
on their brains than those without aura (Wolf et al., 2009). Aura
may be a subjective symptom associated with cortical
spreading depression (CSD). CSD is a process in which a
wave of spreading depolarization spreads through gray matter.
Although it is unclear whether cortical spreading depression
occurs in all migraine patients, because it may be subclinical,
in animal models CSD produces swelling of neurons, distortion
of dendritic spines, a large change of the slow electrical
potential, and silencing (depression) of brain electrical activity.
While there is an acute reversal or recovery of the process
(clinically manifest in migraine with aura), subclinical events
may contribute to underlying brain dysfunction with persistence
of changes (Fioravanti et al., 2011). In familial hemiplegic
migraine mice mutants, there is an increased susceptibility to
CSD, and spreading depression is observed in cortex, basal
ganglia, diencephalon, and hippocampal regions (Eikermann-
Haerter et al., 2011).
CSD may induce spreading ischemia (Dreier, 2011). Some-
what related to the potential alterations on brain systems
induced by CSD (i.e., neuronal death [Sadeghian et al., 2011])
is the increased incidence of subclinical brain lesions or stroke
associated with migraine, particularly in migraine with aura
(Kruit et al., 2010; Pezzini et al., 2007). This is an example of
a feedforward allostatic load process associated with migraine.
The process may result from platelet activation or an altered
endothelial or coagulopathic state (Cavestro et al., 2011; Pezzini
et al., 2007). While thrombosis and migraine may be comorbid,
the usually microthrombotic events contribute to microinfarcts
in this population and also major strokes, usually occurring in
the posterior circulation.
Brain Functional Disruption
Increased responses to sensory stimuli in migraineurs are
observed interictally and include pain (allodynia), phonophobia,
photophobia, and osmophobia. All of these changes are as a
consequence of maladaptation with the disease. With repeated
attacks there is evidence of central sensitization of sensory
systems. Acute allodynia (pain to a normally nonnoxious stim-
ulus) is present in over 50% of patients; interictal allodynia is
present in over a quarter of patients, greater still in patients
who have aura (Lovati et al., 2008). The lowering of the pain
threshold with repeated attacks may then allow for further
attacks that contribute to chronification that is mediated in part
by medication overuse (Zappaterra et al., 2011). During the
interictal period, episodic and chronic migraineurs are more
sensitive to thermal stimulation than nonmigraine controls
(Schwedt et al., 2011). In children with migraine, quantitative
sensory testing to tonic heat applied to the trigeminal area shows
increased sensitivity (Zohsel et al., 2006). Thus, alteration in
sensory processing reflects changes in brain systems that are
a consequence of migraine load. Some have suggested that
cutaneous allodynia is associated with migraine progression
(Bonavita and De Simone, 2010). Other systems also show
central sensitization even during the interictal period: phonopho-
bia, osmophobia (Sjo¨strand et al., 2010), and photophobia
(Purdy, 2011). Abnormal brain activity is present in studies of224 Neuron 73, January 26, 2012 ª2012 Elsevier Inc.allodynia (Burstein et al., 2010), olfactory hypersensitivity
(Demarquay et al., 2008), and photophobia (Denuelle et al.,
2011), all showing increased excitability. Such changes point
to significant functional rewiring of the brain.
Migraine Progression and Transformation
Perhaps disease progression (increased frequency of attacks),
transformation, or chronification (transformation from episodic
to chronic migraine) of the brain state from low-frequency
episodic migraine to high-frequency episodic migraine and
then to chronic migraine (Bigal and Lipton, 2011) is the sine-
qua-non of a measure of allostatic load in this clinical condition.
About 6% of migraineurs progress to high-frequency episodic
headaches, characterized by 105–179 headache days/year
(Bigal and Lipton, 2008). Three percent of individuals in the
general population with infrequent episodic headache progress
to chronic daily headache (CDH) each year, and approximately
2.5% of patients with episodic migraine develop new-onset
chronic migraine (Manack et al., 2011). Given the approximately
8 per 1000 of the population (Lyngberg et al., 2005), or a one-year
prevalence of episodic migraine in the US of nearly 12% (Lipton
et al., 2007), these percentages translate into millions of patients
at risk for progression or transformation. In addition, given the
lack of a specific marker, these numbers may be underrepre-
sented. Progression may be due to mechanisms generating
the migraine attacks or to the consequences arising from the
attacks (Aguggia and Saracco, 2010). This is a typical model
for brain-induced maladaptation to stress that is the establish-
ment of an ‘‘allostatic state’’ of elevated and dysregulated
activity of mediators that normally produced adaptation. From
a biological point of view, neural systems have become less
responsive to treatments, more sensitive to stressors, and over-
all less adaptive to normal activities of daily living (Raggi et al.,
2010).
Downstream Effects of Brain Changes on Systemic
Physiology
Migraine can also produce effects that influence systemic phys-
iology as well as the brain (e.g., insulin dysregulation, leptin,
ghrelin, inflammation). These systemic mediators of allostasis
may have effects in the periphery and in the brain and may
also interact to regulate each other, resulting in nonlinearity of
effects (McEwen, 2006a, 2007). Two examples are alterations
in cytokines and insulin resistance, which are briefly discussed
here. Proinflammatory cytokines are involved in migraine
(Bockowski et al., 2009). For example, significant increases in
IL-6 are observed in migraine (Gergont et al., 2005), and
increases in brain-derived neurotropic factor (BDNF) (Tanure
et al., 2010) during migraine attacks have been reported in
migraine patients. The roles of cytokines such as IL-1 seem to
be many, including the observation that IL-1 stimulates CGRP
release in the trigeminal ganglia cells (Neeb et al., 2011). Such
insights are important because therapies can alter cytokine
levels (Hirfanoglu et al., 2009) that may correlate with the clinical
response and treatments targeted in this area, including anti-
leukotrienes (Riccioni et al., 2007). Such pharmacotherapeutic
approaches have been suggested in other stress-related
disorders (Covelli et al., 2005). In the second example, insulin
resistance is reported in migraine patients (Guldiken et al.,
2008). In one report, migraine occurred with the onset of
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that a metabolic insult contributed to the CNS manifestation of
headache (Split and Szydlowska, 1997). Impaired tolerance to
glucose is present during migraine attacks (in patients who
acted as their own controls) (Shaw et al., 1977). Such data,
taken together with more recent information, suggest specific
changes related to hyperinsulinemia in migraine (e.g., elevated
levels of glucagon-like peptides and leptin, even in nonobese
female migraineurs [Bernecker et al., 2010]). Targeting such
risk factors that are easily measured may offer new therapeutic
opportunities.
Disturbance of the autonomic nervous system is a primary
characteristic of migraine, and some authors have suggested
an underlying chronic sympathetic dysfunction in the disorder
(Peroutka, 2004). Spontaneous baroreflex sensitivity and heart
rate variability (HRV) are different in migraine patients compared
to healthy controls (Nilsen et al., 2009). Neural systems,
including the prefrontal cortex, control parasympathetic control
of the heart via the vagus nerve and also regulate inflammation
(Thayer, 2009); in addition, decreases in heart rate variability
are associated with a variety of changes (e.g., increased proin-
flammatory cytokines, acute phase protein, increased cortisol,
increased fasting glucose), all of which relate to increased allo-
static load.
Migraine is associated with alterations in sleep (Rains et al.,
2008). In chronic migraine, altered hormone secretion has been
reported for prolactin (decreased nocturnal peak), melatonin
(delayed nocturnal peak), and cortisol (increased concentra-
tions) (Peres et al., 2001), suggesting that the condition has
produced changes in circadian regulation. Sleep deprivation
and circadian disruption is itself a source of stress and allostatic
load (Spiegel et al., 1999). ‘‘The way sleep impacts next day
mood/emotion is thought to be affected particularly via
REM-sleep, where we observe a hyperlimbic and hypoactive
dorsolateral prefrontal functioning in combination with a normal
functioning of the medial prefrontal cortex, probably adaptive
in coping with the continuous stream of emotional events we
experience’’ (Vandekerckhove and Cluydts, 2010). Indeed,
migraine (along with disorders such as depression and gastric
ulcers) is an independent predictor of excessive daytime sleep-
iness (Stroe et al., 2010). The basis for this may be an abnormal
(reduced) arousal index in rapid eye movement (REM) sleep,
which implicates dysfunction in hypothalamic and brainstem
regions (Della Marca et al., 2006). Abnormal sleep or sleep
restriction can have negative consequences for brain function
and peripheral physiology (Kim et al., 2007), including increased
appetite and energy expenditure, increased levels of proinflam-
matory cytokines, decreased parasympathetic and increased
sympathetic tone, increased blood pressure, increased evening
cortisol levels, and elevated insulin and blood glucose (McEwen,
2006b). Clearly, sleep disturbances and migraine (both allodynic
and nonallodynic) have complex interactive effects on each
other (Lovati et al., 2010) that suggest that implementing
congruent therapeutic approaches may be of significant
importance.
Pharmacological Disruption of Allostasis
Medications may be allostatic moderators or exacerbators. In
migraine, the overuse of triptans and opioids seems to induceor contribute to chronification of migraine (Bigal, 2009). Cortico-
trophic and somatotrophic functions are significantly impaired
in chronic migraine medication overuse (CM-MOH) patients:
after human corticotrophin-releasing hormone (hCRH) admin-
istration, ACTH and cortisol concentrations are significantly
higher in CM-MOH cases than in controls (Rainero et al.,
2006). Drugs such as sumatriptan induce a significant decrease
of ACTH, cortisol, and prolactin concentrations, both in patients
with migraine and in controls (Rainero et al., 2001). Acute subcu-
taneous administration of sumatriptan activates the pituitary-
adrenal axis: significant increases in b-endorphin and cortisol
concentrations are reported across all subjects receiving suma-
triptan (Facchinetti et al., 1994), and these would produce
secondary effects. Migraine medications may also alter sensory
processing. For example, the administration of sumatriptan to
healthy volunteers produces abnormal psychophysiological
(diminished pleasantness) and fMRI signal (in anterior insular,
lateral orbitofrontal, and anterior cingulate cortices and medial
thalamus) changes that are observed only following sumatriptan,
not saline (Kra¨mer et al., 2007).
In addition to exogenously administered drugs, endogenous
chemical (hormonal) milieu can also be a significant issue in
migraine. About 17% of women versus 6% of men get migraines
(Rasmussen et al., 1991). Perhaps the best example of induced
stressors on brain systems is the female menstrual cycle (Farage
et al., 2008). Menstrual migraine (MM) is common in women and
may relate to hormonal modulations in the GABA-A receptors
decreasing normal inhibitory control (Epperson et al., 2002).
Menstrual migrainemay bemore difficult to treat than nonmenst-
rual migraine in women, suggesting a role of induced resistance
as a result of their hormonally induced migraine. Menstrual
migraine may also be a contributor to the evolution of chronifica-
tion of headache (Lay and Broner, 2008). Conversely, elimination
of MM with the use of hormonal preventive medications can be
achieved in a large percentage of patients, and this further
decreases chronicmigraine that is present in over 90%ofwomen
(Calhoun and Ford, 2008). It would thus seem that the alterations
induced in brain systems that induce menstrual migraine may
add to the allostatic load/overload. Estrogen (estradiol) and
progesterone (via allopregnanolone) affect neuronal systems
with opposite effects, with estrogen generally being excit-
atory—enhancing glutamatergic systems and progesterone
inhibitory—through GABA systems (Finocchi and Ferrari, 2011).
Progesterone usually antagonizes estradiol in synaptic remodel-
ing in brain regions, including the hippocampus (Wong et al.,
2009). Increased brain sensitivity in women includes catamenial
epilepsy, in which hormonal changes, particularly estrogen,
contribute to increased seizures (Guille et al., 2008). A similar
process may take place in migraine. The effects of estradiol on
brain systems is complex and may induce excitatory-induced
neuronal changes (Blacklock et al., 2005) butmay also beprotec-
tive of adrenal steroids (Garcia-Segura et al., 2007). The higher
prevalence of stress-related disorders in women may relate to
estrogen effects on brain systems that have high levels of both
genomic and nongenomic estrogen receptors (viz., hypothal-
amus, amygdala, hippocampal formation, brainstem, thalamus,
and entorhinal cortex, including the limbic system [McEwen
and Milner, 2007; Osterlund and Hurd, 2001]).Neuron 73, January 26, 2012 ª2012 Elsevier Inc. 225
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Allostatic Load
Reports of cognitive testing in adult migraineurs and controls
have yielded inconsistent results, but migraine patients with
aura experience more neuropsychological deficits than migraine
patients without aura (O’Bryant et al., 2005). Diffusion tensor
imaging data shows changes in gray matter suggestive of
a possible basis for cognitive dysfunction (Rocca et al., 2006).
However, migraine has been reported to be associated with
lower cognitive processing and intelligence quotient and verbal
intelligence quotient scores (Parisi et al., 2010) in some studies
(De Ciantis et al., 2008; Kalaydjian et al., 2007), whereas others
reporting on the lifetime diagnosis of migraine show that it is
not associated with cognitive deficits in middle age (Gaist
et al., 2005).
The brain responds in different ways to different stressors
that seems to be age dependent (see Ferriero and Miller,
2010). There are times of major changes in the developing brain
during which stress affects adaptation. Early life stressors may
program stress circuits, thereby producing alterations in the
neuroendocrine phenotype with subsequent maladaptation,
resulting in susceptibility to disease or altered responses to
treatments (Markham and Koenig, 2011). Migraines affect
preadolescent children and become more manifest after
puberty (Bigal and Arruda, 2010). Migraine often lasts less
than 1 hr in young children. In some children, progression is
present (Bigal and Arruda, 2010). Chronic daily headache
affects 2%–4% of adolescent females and 0.8%–2% of
adolescent males (Cuvellier et al., 2008; Wang et al., 2006).
Treatments may also alter cognitive and executive function in
childhood (Pandina et al., 2010) and may also be considered
as potential modifiers of allostatic load. Predisposing factors
to migraine are not well defined. Some data suggest that
conditions such as seizures may be linked with migraine later
in life (Bianchin et al., 2010). However, a growing body of liter-
ature suggests that early life stress may be associated with
migraine (Tietjen and Peterlin, 2011) and may be a risk factor
for migraine chronification. The long-term consequences of
migraine on the developing brain are not known, but even
prenatal exposure to stressors and exposure to stressor in
childhood may alter the ‘‘trajectory of brain development’’
(Markham and Koenig, 2011). Regions involved in cognitive
and affective functions that undergo prolonged postnatal devel-
opment (frontal regions) and stress (amygdala) are vulnerable
targets that may be affected as a result of early life stress
(Pechtel and Pizzagalli, 2011).
Brain Regions in Migraine: Targets of Allostatic Load
A central role of the brain in stress and adaptation relates to how
specific regions respond and, in doing so, may undergo stress-
induced structural and/or functional changes (McEwen, 2007).
Although it is now well documented that migraine is associated
with structural (May, 2006) and functional (ictal hyperalgesia
and allodynia and interictal neural excitation [Marcus, 2003])
changes, recent research has implicated changes in the very
regions noted in the general stress response. Stress or cyto-
kine-induced release of glucocorticoids normally produce
immunosuppressive and anti-inflammatory changes but may226 Neuron 73, January 26, 2012 ª2012 Elsevier Inc.have other effects in the brain (Sorrells et al., 2009). Chronic
elevated levels of cortisol impair synaptic plasticity, diminish
neurogenesis and spinal density, and may result in dendritic
atrophy (McEwen and Magarinos, 2001) and dysregulate gluta-
mate neurotransmission (Iyo et al., 2010). Such changes may
contribute to alterations in brain regions such as the hippo-
campus that may manifest as syndromes associated with
migraine, such as depression (Musazzi et al., 2011). Data sup-
porting increases in stress hormones including noradrenaline
and cortisol in response to stress in migraineurs have been
reported (Leistad et al., 2007), thus providing a basis for specific
brain-induced changes in migraine. Migraine is considered to
be a hyperexcitable state, and increases in excitatory neuro-
transmitters during the interictal period may reflect such a state
(Prescot et al., 2009).
Of the brain regions studied, the hippocampus, amygdala,
hypothalamus, and prefrontal cortex seem to play an important
role in this process. Some regions such as the hippocampus
and prefrontal cortex are responsive to the repeated action of
glucocorticoids, together with excitatory amino acids and other
mediators, on the brain region that affect hippocampal function
and structure (McEwen, 2007). The hippocampus has been
a model for understanding the effects of stress on neuronal
plasticity and allostatic load (McEwen, 2001). In stressful
conditions, neurogenesis and apoptosis in hippocampus are
suppressed (Kubera et al., 2011). Such a situation could be
operating every time an individual has a migraine attack. The
process may involve other brain regions that have connections
with the hippocampus, including the hypothalamus and the
amygdala. For example, with unpredictable stress, inhibitory
input to neurons involved in the hypothalamus are reportedly
suppressed, leading to dysregulation of the axis and potentially
overexposure of the brain to glucocorticoids (Joe¨ls et al., 2004)
In addition, a putative role for the amygdala in allostatic load,
related to anticipatory anxiety, has been suggested (Schulkin
et al., 1994). The involvement of the amygdala in migraine
has been supported by a number of other reports, including
changes related to cortical spreading depression (Dehbandi
et al., 2008); chronic migraineurs show decreased amygdala
volume (Valfre` et al., 2008). Its role in this may relate to the
high levels of anxiety or fear in patients with migraine (Casucci
et al., 2010), particularly in those suffering from chronic daily
migraine (Dodick, 2009).
Given the role of the hypothalamus in autonomic control (viz.,
neuroendocrine, homeostasis, pain modulation, sleep-wake
cycle, food intake), its overall role in the stress response, and
its connections with multiple brain regions, the hypothalamus
is central to the effects of stress on the brain (Baumann and
Turpin, 2010). Measures of altered hormone are reported in
chronic migraine patients (including prolactin, cortisol, and
melatonin), which is indicative of abnormalities in circadian
biology (Peres et al., 2001). Thus, the hypothalamus may
control systems that could have many functional implications
through such alterations in hormone and autonomic function,
impinging on many organ systems, including the brain. One
example is that of the association of obesity and migraine
(Peterlin et al., 2010). Alterations in hypothalamic control
may be manifest and contribute to both syndromes, because
Figure 5. Migraine Disease State and
Increasing Allostatic Load
The figure shows examples of increased burden of
disease as a consequence of increased migraine
frequency. The changes affect both brain and
body processes. Disease burden may be defined
as the personal cost of migraine in terms of
medical, economic, social, financial, personal, or
family costs.
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may be abnormal in both conditions.
Uncoupling Allostatic Overload in Migraine:
Adaptive Plasticity
Given that there may be multiple stressors that contribute to the
allostatic load (Figure 4) and increased disease burden with
chronification (Figure 5), ideally, one could evaluate and quantify
each and provide a rational approach to devolving, uncoupling,
diminishing direct inputs onto systems that modulate the allo-
static load and directly impact those systems that have been
altered. A new approach to defining and measuring the relative
contributions and their cumulative or additive effects would bring
opportunities to improve diseases such as migraine where we
only have a limited response in terms of preventing the attacks
and/or treating chronic migraine. Specifically, the following
principles would seem to be salient: (1) intervene as early as
possible to prevent the negative cascade; (2) top-down interven-
tions (e.g., exercise, social support, stress reduction, diet, etc.
[see McEwen and Gianaros, 2011]) to help reestablish systemic
and brain ‘‘balance,’’ which may include plastic changes and
neuronal connectivity (Castre´n, 2005); (3) pharmacotherapy
may contribute to the top-down process and may be more
efficacious in the context of other modulators of allostasis. One
example in support of interactive effects is the use of antidepres-
sants in the context of a positive therapeutic environment andNeuron 73the notion that multiple therapies may
be more beneficial than a single treat-
ment (March et al., 2004). Another
example in support of our proposal is
the efficacy of antidepressants, along
with physiotherapy, in recovery of motor
function after stroke (Chollet et al.,
2011). (4) On the other hand, as noted
above, somemedications may contribute
to the allostatic overload and make the
condition worse. Thus, targeting treat-
ments in the context of modification of
multiple neurobiological systems would
seem like a rational process to implement
at a clinical level. Specific targets include
behavioral targets (including sleep and
stress modification), but also those
directed at brain systems, as noted
below.
Neuronal Stabilizers
Given the evidence that migraine may
be a hyperexcitable state, drugs thatmay diminish this state may be useful in migraine prevention.
Currently, topiramate is the only FDA-approved drug
for migraine prevention (Silberstein et al., 2007). Evidence for
a specific mechanism related to this is suggested to act by a
kainate receptor antagonism on brain system, as well as the tri-
geminovascular system (Andreou and Goadsby, 2011).
Magnetic resonance spectroscopy (MRS) studies support this
notion, because topiramate may alter GABA levels in the brains
of healthy subjects (Moore et al., 2006).
Network Modification
The notion that treatments alter networks through changes in
functional and morphological connectivity is not novel. Progres-
sive plasticity of neuronal systems (e.g., spine morphology,
dendritic branching, etc.) by medications has been considered
in other diseases such as depression. In the latter condition,
therapeutic effects may be delayed and should be a focus of
evaluation of treatment efficacy throughout the brain (Baudry
et al., 2011). Thus, the clinical effects may include inducing
altered neurogenesis in specific regions, such as the hippo-
campus, that may contribute to clinical improvement through
blockade of stress signals (Warner-Schmidt and Duman,
2006). Furthermore, alterations in neuronal activity can elicit
long-lasting changes in the synaptic strength transmission at
excitatory synapses, and drugs or disease may modify dendritic
spine density and thus synaptic contacts (Malenka, 2003). Such
changes have significant effects on networks that can now be, January 26, 2012 ª2012 Elsevier Inc. 227
Figure 6. Modification of Allostatic Overload through Multiple Targeted Effects on Stressors that Modulate Specific Brain Systems
The figure shows how multiple targeted treatments may contribute to migraine regression. The relative effects of target-specific treatments may have complete,
complementary, or no effect on various migraine symptoms. Taken together, these decrease an overall severity score.
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Perspectiveevaluated using a technique in neuroimaging that measures
multiple low-frequency changes in brain systems called resting
state networks (RSNs) (De Martino et al., 2011).
Neurohormonal Tempering
Migraine generally improves after menopause or with hormonal
therapies (Calhoun and Hutchinson, 2009). Neurohormonal
modulation, including gonadal and glucocorticosteroids and
insulin, clearly has implications on brain modification. For
example, estrogen is known to be excitatory, and glucocorti-
coids also have excitatory effects throughout the brain (see
above). Indeed, modification of repeated migraines induced by
menstrual period has been reported to diminish migraine burden
(Calhoun and Ford, 2008). Another example relates to the orexin
(a neuropeptide released by the posterior lateral hypothalamus)
system in augmenting treatment of sleep in migraine (Scammell
and Winrow, 2011). However, some hormonal therapies may
make migraine worse or add significant risks. For example,
combined contraceptives (which have estrogen and proges-
terone) are contraindicated inmigraine with aura andmay induce
ischemic stroke (Allais et al., 2009). Some migraine conditions
improve after pregnancy (e.g., menstrual migraine) (Silberstein,
2001).
Inhibiting Neuronal Gain
Insights into the headache of migraine pain as it progresses from
premonitory symptoms to the headache itself and then the
persistence of the headache relate to progressive enhancement
of neural assemblies from nociceptors in the trigeminal ganglion
to the trigeminal nucleus and then thalamic and cortical regions
(Burstein et al., 2010). This has been termed central sensitization.
Early initiation of treatment seems to halt the migraine attack,228 Neuron 73, January 26, 2012 ª2012 Elsevier Inc.whereas delayed treatments may not have any benefit (Burstein
et al., 2004), stemming the negative feedforward cascade. In
some ways, this is a metaphor for all other aspects of migraine
treatments.
Modulating Brain Circuits with Neurostimulation
In recent years, a number of neuromodulation approaches have
been used via various neurostimulation techniques in migraine
(Dafer, 2010) that may alter neural networks. Most approaches
are noninvasive (e.g., transcranial magnetic stimulation [TMS;
Lipton and Pearlman, 2010]), whereas some are invasive
(e.g., vagal nerve stimulation [Lenaerts et al., 2008] or deep brain
stimulation for cluster headaches [Franzini et al., 2010]). Interest-
ingly, some data suggest significant improvement, even in
patients who have had migraine for years. It is assumed that
TMS techniques alter neural connectivity through alteration in
neural excitability.
Taken together, the above issues relate to modulating brain
circuits and neuroconnectivity. Top-down strategies that con-
trol stress through targeted neurobiological mechanisms may
progressively diminish allostatic load with expected improve-
ment of symptoms (Figure 6). Clearly, the latter is dependent
on ‘‘readjusted’’ neural networks, because brain function defines
behavior.
Allostatic Load and Other Pain Conditions
Although we have focused on migraine as a model brain disease
of allostatic load, we would suggest that similar abnormal
allostasis may apply to chronic pain. Although a complete
description of this is beyond the scope of this review, we provide
a summary of processes relating to allostatic load that may be
Neuron
Perspectiveobserved in chronic pain. (1) Stress as an issue in chronic pain
disorders is reported in the literature of fibromyalgia (Martinez-
Lavin and Vargas, 2009) and pain associated with depression
(Hammen, 2005). Fibromyalgia and migraine are common
disorders and may have similarly underlying neuroendocrine
dysfunction (Valenc¸a et al., 2009). Some chronic pain conditions
are more likely in those who have had prior stress (e.g., child-
hood abuse [Schofferman et al., 1993]) or posttraumatic stress
disorder (Defrin et al., 2010) or other lifetime traumas (Sledjeski
et al., 2008). Some ‘‘evoked’’ stressors common to exacerbating
bothmigraine and chronic pain conditions include environmental
factors such as barometric change (Mukamal et al., 2009) or
emotional stressors (Hertig et al., 2007). (2) The issue of under-
lying pathophysiology between chronic pain and migraine may
have an overlapping feature in so-called chronic nociceptive
pain, as observed in arthritis. Both structural and functional
changes have been observed in patients with rheumatoid (War-
tolowska et al., 2011) and osteoarthritis (Gwilym et al., 2010).
These are progressive disorders that usually start off with pain
(that may follow an injury) and then progress to osteoarthritis
over years (Thorstensson et al., 2009). Thus, there are some
parallels with the migraine model regarding the intermittent
pain presentation that may show chronification. Such alterations
may manifest both in chronic pain and in migraine as changes
in emotional or cognitive processing (Apkarian et al., 2004).
The underlying process of chronification from acute injury to
chronic pain may have some parallels that include a feedforward
process. (3) Chronic pain andmigraine both demonstrate central
sensitization (Woolf, 2011) and allodynia (Schwedt et al., 2011).
In addition, intermittent pain may be common to diseases such
as back pain, in which there is an underlying and continuous
(albeit fluctuating) spontaneous background or ongoing pain,
as well as exacerbations related to evoked stimuli (viz., mechan-
ical, chemical).
Conclusions and Future Opportunities
The allostatic load model expands the stress-disease literature
by proposing a temporal cascade of multisystemic physiolog-
ical dysregulations that contribute to disease trajectories
(Juster et al., 2010) in the brain and body. Allostatic load in
migraine represents the cumulative effects of the disease, as
well as its treatment, on brain systems with effects throughout
the body via the neural and endocrine effects upon systemic
physiology. As such, a number of important conclusions can
be made. First, early interruption of a feedforward vicious cycle
that involves not only the brain but also other systems of the
body that can cause problems in key brain areas, as well as
systemic pathophysiology, is a key component to diminishing
allostatic load. Second, although current clinical practice for
migraine frequently utilizes multimodal techniques (medication,
stress reduction, etc.), these are rarely quantified. The allostatic
model in migraine allows the implementation of a bio-psycho-
social model that can be systematically measured to define
how different systems interact to impact the allostatic load
of the disease. Insights based on such research on the role
of allostatic load in migraine may provide a foundation to
improve health outcomes through methods that manage stress
(Ganzel et al., 2010). Fortunately, the brain is a plastic organ,and adaptations can be brought about by treatments that alter
allostatic load.
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